MiMedx Group (NASDAQ:MDXG) Issues Quarterly Earnings Results

Posted by Francis Steltz on Jul 29th, 2026

MiMedx Group (NASDAQ:MDXG – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05), FiscalAI reports. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The company had revenue of $64.36 million during the quarter, compared to analysts’ expectations of $63.46 million.

Here are the key takeaways from MiMedx Group’s conference call:

Sanara MedTech acquisition: MiMedx agreed to acquire Sanara for $35 per share, creating a combined regenerative medicine company expected to generate more than $400 million in 2027 revenue, double-digit growth, over 20% adjusted EBITDA margins, and at least $20 million in annual cost synergies.
Surgical momentum remained strong: Second-quarter surgical revenue increased 15% year over year, with broad-based growth across the portfolio, while the Sanara deal is expected to expand MiMedx’s surgical addressable market by approximately $4 billion.
Wound care showed early stabilization: Wound revenue rose 11% sequentially and volume increased 22%, including 44% sequential growth in wound care centers, but revenue remained down 61% year over year because of substantially reduced Medicare reimbursement and ongoing administrative challenges.
Second-quarter profitability deteriorated: Net sales fell 35% year over year to $64 million, adjusted EBITDA was negative $8 million, and gross margin declined to 69%; results included an additional $5 million bad-debt charge tied mainly to private-office accounts.
Financing and outlook: MiMedx reiterated 2026 standalone revenue guidance of $260 million to $290 million and expects adjusted EBITDA to approach breakeven, while financing the Sanara acquisition with a $300 million term loan carrying interest at SOFR plus 6.25%.

MiMedx Group Price Performance

MDXG traded down $0.13 during midday trading on Wednesday, reaching $4.23. 1,421,925 shares of the company’s stock were exchanged, compared to its average volume of 1,279,335. MiMedx Group has a 1-year low of $3.03 and a 1-year high of $7.99. The stock has a market capitalization of $629.61 million, a PE ratio of 21.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.39 and a quick ratio of 4.81. The business’s 50-day moving average price is $3.89 and its 200 day moving average price is $4.27.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Craig Hallum lowered their price target on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Citizens Jmp reduced their price objective on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, April 30th. Wall Street Zen downgraded MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings lowered MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Check Out Our Latest Research Report on MiMedx Group

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MDXG. Kemnay Advisory Services Inc. purchased a new stake in MiMedx Group in the 4th quarter valued at approximately $48,000. Jain Global LLC purchased a new stake in shares of MiMedx Group in the fourth quarter valued at $73,000. Virtu Financial LLC purchased a new stake in shares of MiMedx Group in the fourth quarter valued at $78,000. Headlands Technologies LLC acquired a new stake in shares of MiMedx Group during the second quarter valued at $72,000. Finally, Cresset Asset Management LLC acquired a new stake in shares of MiMedx Group during the third quarter valued at $86,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.